Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells for Myelodysplastic Syndrome
Study Summary
This trial is testing donor natural killer cells as a treatment for leukemia. The goal is to find out if it is safe and if it has any side effects.
- Myelodysplastic Syndrome
- Acute Recurrent Myeloid Leukemia
- Bone Marrow Blast 10% or Higher
- Allogeneic Stem Cell Transplant Recipient
- Refractory Acute Myelogenous Leukemia
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 8 Secondary · Reporting Duration: Up to 63 days
Trial Safety
Safety Progress
Trial Design
4 Treatment Groups
Cohort II (fludarabine, decitabine, NK cell therapy)
1 of 4
Induction
1 of 4
Cohort I (fludarabine, cytarabine, NK cell therapy)
1 of 4
Conditioning Regimen
1 of 4
Experimental Treatment
30 Total Participants · 4 Treatment Groups
Primary Treatment: Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 80 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Is it feasible for individuals to join this clinical trial?
"Indications from clinicaltrials.gov suggest that this medical experiment is still open to applicants, with the initial advertisement dated June 1st 2020 and most recent updates published on February 7th 2022." - Anonymous Online Contributor
To what illnesses is Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells commonly applied?
"Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells has been proven to be a viable treatment for individuals in intermediate 2 risk category of ipss, who are afflicted with refractory anemias or blast phase chronic myelocytic leukemia." - Anonymous Online Contributor
Is it feasible for me to participate in this medical study?
"This clinical trial is selecting up to 30 patients who suffer from a certain syndrome and are over 18 years old, but under 80." - Anonymous Online Contributor
What does this clinical investigation aspire to discover?
"This trial, which will span 28 days, seeks to determine the Maximum Tolerated Dosage of membrane-bound interleukin-21-expanded haploidentical natural killer (NK) cells. Descriptive statistics are used to measure secondary outcomes such as Median Time for Neutrophil and Platelet Count Recovery, Median Duration of Remission, and Percentage of Patients Rendered Transplant Eligible by this Regimen." - Anonymous Online Contributor
What evidence exists to suggest that Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells have been successfully tested in the past?
"Currently, there are 677 studies examining the efficacy of Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells with 82 trials in their final testing phase. Grand Rapids is hosting a significant number of these assessments however, 13389 medical centers globally offer this treatment." - Anonymous Online Contributor
Is this research study offering enrollment to those over thirty years of age?
"This clinical trial is searching for participants of age 18 years or older, but less than 80." - Anonymous Online Contributor
What is the scope of this research project in terms of participants?
"Indeed, according to the information located on clinicaltrials.gov, this medical experiment is currently recruiting individuals for participation. Its initial posting date was June 1st 2020 and it has been updated most recently on February 7th 2022. This study requires 30 volunteers from a single site." - Anonymous Online Contributor
Could you elucidate any health risks associated with Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells treatment?
"As this is a Phase 1 trial with limited safety and efficacy data, our team at Power has assessed the safety of Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells to be an estimated score of 1." - Anonymous Online Contributor